National Prescribing Trends of Direct-Acting Antivirals for Hepatitis C

National prescribing of hepatitis C direct-acting antivirals peaked at 185,677 treatment courses in 2015 but has since fallen to about 69,000 annually, far below the level needed to achieve national elimination targets. Despite shifts toward treatment among Medicaid patients, younger adults, and rural populations, overall treatment volume remains insufficient to reduce national prevalence. These findings highlight the need for expanded screening, rapid treatment models, and policy reforms to accelerate treatment in the US.